EA202092229A1 - Мутеины cd4 и способы их применения - Google Patents

Мутеины cd4 и способы их применения

Info

Publication number
EA202092229A1
EA202092229A1 EA202092229A EA202092229A EA202092229A1 EA 202092229 A1 EA202092229 A1 EA 202092229A1 EA 202092229 A EA202092229 A EA 202092229A EA 202092229 A EA202092229 A EA 202092229A EA 202092229 A1 EA202092229 A1 EA 202092229A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
muteins
application
proteins
domain
Prior art date
Application number
EA202092229A
Other languages
English (en)
Inventor
Майкл Фарзан
Мэттью Гарднер
Ина Фетцер
Майкл Альперт
Чарльз Бейли
Original Assignee
Зе Скриппс Рисёрч Инститьют
Иммьюн, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зе Скриппс Рисёрч Инститьют, Иммьюн, Инк. filed Critical Зе Скриппс Рисёрч Инститьют
Publication of EA202092229A1 publication Critical patent/EA202092229A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к белкам, которые содержат домен 1 CD4 и домен 2 CD4 (CD4 D1D2), причем указанный CD4 D1D2 содержит одну или более мутаций по сравнению с CD4 D1D2 человека дикого типа, и к способам применения указанных белков для лечения инфекции вируса иммунодефицита человека (ВИЧ) у субъекта.
EA202092229A 2018-03-21 2019-03-21 Мутеины cd4 и способы их применения EA202092229A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862645903P 2018-03-21 2018-03-21
PCT/US2019/023422 WO2019183387A1 (en) 2018-03-21 2019-03-21 Cd4 muteins and methods of using the same

Publications (1)

Publication Number Publication Date
EA202092229A1 true EA202092229A1 (ru) 2021-07-05

Family

ID=67986365

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092229A EA202092229A1 (ru) 2018-03-21 2019-03-21 Мутеины cd4 и способы их применения

Country Status (13)

Country Link
US (1) US20230159616A1 (ru)
EP (1) EP3768293A4 (ru)
JP (2) JP7490632B2 (ru)
KR (1) KR20200144549A (ru)
CN (1) CN112188897A (ru)
AU (1) AU2019240319A1 (ru)
BR (1) BR112020019107A2 (ru)
CA (1) CA3094691A1 (ru)
EA (1) EA202092229A1 (ru)
IL (1) IL277458A (ru)
SG (1) SG11202009194XA (ru)
WO (1) WO2019183387A1 (ru)
ZA (1) ZA202006480B (ru)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2087017A1 (en) * 1990-07-11 1992-01-12 Mary E. Brawner Streptomyces vectors for production of heterologous proteins
WO2007075414A2 (en) * 2005-12-14 2007-07-05 The Trustees Of Columbia University In The City Of New York Chemically derivatized cd4 and uses thereof
US20130108653A1 (en) * 2009-12-22 2013-05-02 Shervin Bahrami Bivalent molecules for hiv entry inhibition
US20110305670A1 (en) * 2010-06-10 2011-12-15 President And Fellows Of Harvard College Nucleic acid encoding fusion polypeptides that prevent or inhibit hiv infection
WO2014150748A2 (en) * 2013-03-15 2014-09-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Stabilized single human cd4 domains and fusion proteins
US10626161B2 (en) * 2015-04-28 2020-04-21 The Scripps Research Institute Methods and compositions for protection against lentiviral infections

Also Published As

Publication number Publication date
CN112188897A (zh) 2021-01-05
JP7490632B2 (ja) 2024-05-27
EP3768293A1 (en) 2021-01-27
BR112020019107A2 (pt) 2020-12-29
AU2019240319A1 (en) 2020-11-12
ZA202006480B (en) 2022-01-26
IL277458A (en) 2020-11-30
WO2019183387A1 (en) 2019-09-26
CA3094691A1 (en) 2019-09-26
KR20200144549A (ko) 2020-12-29
EP3768293A4 (en) 2022-07-06
SG11202009194XA (en) 2020-10-29
JP2021518171A (ja) 2021-08-02
JP2024041907A (ja) 2024-03-27
US20230159616A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
EA201891028A1 (ru) Триспецифические и/или тривалентные связывающие белки для предупреждения или лечения инфекции, вызываемой hiv
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
MA43763B1 (fr) Protéine f de pré-fusion du vrs soluble et stabilisée pour son utilisation dans la prophylaxie d'une infection vrs
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201992784A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
EA200901490A1 (ru) Химические соединения
EA201992083A1 (ru) Модуляторы соматостатина и их применения
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
EA202190854A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
PH12020551492A1 (en) Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
EA201892203A1 (ru) Оксабороловые сложные эфиры, их применение
EA201990988A1 (ru) Антитела против chikv и пути их применения
EA201790336A1 (ru) Антитела к ангиопоэтинподобному белку 4 и способы применения
EA202190057A1 (ru) Солюбилизированные апиразы, способы и применение
CL2017003260A1 (es) Dominios variables simples de inmunoglobulina contra proteína f de rsv.
EA202092229A1 (ru) Мутеины cd4 и способы их применения
EA202191758A1 (ru) Пептиды для лечения и профилактики диабета и связанных с ним заболеваний
EA202092045A1 (ru) Лечение и предупреждение преэклампсии
EA202091563A1 (ru) Человеческие антитела к гемагглютинину вируса гриппа
EA201792482A1 (ru) Соединения-пептидомиметики, нейтрализующие вирус гриппа
JOP20180058A1 (ar) أجسام مضادة محيدة لفيروس نقص المناعة البشرية
EA202092732A1 (ru) АНТИТЕЛА, КОТОРЫЕ НАЦЕЛЕНЫ НА ГЛИКОПРОТЕИН gp120 ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА (ВИЧ), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201990041A1 (ru) Композиции, содержащие тимолол, и их применение при лечении розацеа при местном применении
EA202090146A1 (ru) Косметические композиции и способы применения